Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Irinotecan + Panitumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Panitumumab||Vectibix||ABX-EGF||EGFR Antibody 29||Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF G466V||colorectal cancer||predicted - sensitive||Irinotecan + Panitumumab||Case Reports/Case Series||Actionable||In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).||28783719|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04117945||Phase II||Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab||Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer||Recruiting|